Company intelligence / Profile preview

Napigen

Wilmington, Delaware, United Statesnapigen.com ↗

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

Napigen has developed a proprietary platform enabling precise genome engineering of mitochondria and chloroplasts. The company’s initial products are focused on agriculture—improving crop yields, developing herbicide-resistant traits that do not spread via pollen, and mitigating greenhouse gas emissions. They have received patents for their CRISPR-based technology targeting organellar genomes. There are also early efforts toward applying this technology to human health by enabling mitochondrial gene editing in mammalian cells, but no clinical results or trials have been reported yet.

Therapeutic areas: OtherRare Diseases
Modalities: Genome editing
Industry: Agriculture & AgTech

Beyond the preview

Go deeper on Napigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Napigen.

Explore the full profile